Information:
Fel:
ID
34167
Beskrivning
Cardiotoxicity of Adjuvant Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00858039
Länk
https://clinicaltrials.gov/show/NCT00858039
Nyckelord
Versioner (1)
- 2019-01-14 2019-01-14 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
14 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Neoplasms NCT00858039
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
female 18 years or older
boolean
ID.2
Item
histologically confirmed, completely excised invasive breast cancer with her-2 overexpression
boolean
ID.3
Item
primary surgery less than twelve weeks prior to registration
boolean
ID.4
Item
lvef>50% as assessed by transthoracic echocardiogram or gated heart pool scan
boolean
ID.5
Item
eastern cooperative oncology group performance status 0-2
boolean
ID.6
Item
adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy and 52 weeks of trastuzumab
boolean
ID.7
Item
before patient registration, informed consent must be given according to local regulations.
boolean
ID.8
Item
pregnancy
boolean
ID.9
Item
distant metastases from breast cancer
boolean
ID.10
Item
any systemic chemotherapy prior to study entry
boolean